{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigational+RSV+vaccine+1", "query": { "intervention": "Investigational RSV vaccine 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigational+RSV+vaccine+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-03T11:31:54.726Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06686654", "title": "Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Human Metapneumovirus Immunization", "Respiratory Syncytial Virus Immunization" ], "interventions": [ { "name": "Investigational hMPV/RSV vaccine", "type": "BIOLOGICAL" }, { "name": "Investigational hMPV vaccine (monovalent)", "type": "BIOLOGICAL" }, { "name": "Investigational RSV vaccine (monovalent)", "type": "BIOLOGICAL" }, { "name": "Licensed RSV Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Investigational RSV+hMPV vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 1530, "start_date": "2024-11-11", "completion_date": "2027-01-18", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" }, { "city": "Gardena", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06686654" }, { "nct_id": "NCT04909021", "title": "Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus (RSV)" ], "interventions": [ { "name": "Investigational RSV vaccine MV-012-968 (Dosage 1)", "type": "BIOLOGICAL" }, { "name": "Investigational RSV vaccine MV-012-968 (Dosage 2)", "type": "BIOLOGICAL" }, { "name": "Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)", "type": "BIOLOGICAL" }, { "name": "Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)", "type": "BIOLOGICAL" }, { "name": "Placebo (single-dose)", "type": "OTHER" }, { "name": "Placebo (two-dose)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Meissa Vaccines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "36 Months", "sex": "ALL", "summary": "6 Months to 36 Months" }, "enrollment_count": 63, "start_date": "2021-06-03", "completion_date": "2023-10", "has_results": false, "last_update_posted_date": "2022-08-02", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 12, "location_summary": "Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04909021" }, { "nct_id": "NCT07628049", "title": "A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections+Metapneumovirus" ], "interventions": [ { "name": "RSV/hMPV_V low dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_V medium dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_V high dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_W low dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_W medium dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_W high dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_X low dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_X medium dose vaccine", "type": "BIOLOGICAL" }, { "name": "RSV/hMPV_X high dose vaccine", "type": "BIOLOGICAL" }, { "name": "hMPV_Y low dose vaccine", "type": "BIOLOGICAL" }, { "name": "hMPV_Y medium dose vaccine", "type": "BIOLOGICAL" }, { "name": "hMPV_Y high dose vaccine", "type": "BIOLOGICAL" }, { "name": "hMPV_Z low dose vaccine", "type": "BIOLOGICAL" }, { "name": "hMPV_Z medium dose vaccine", "type": "BIOLOGICAL" }, { "name": "hMPV_Z high dose vaccine", "type": "BIOLOGICAL" }, { "name": "Control vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1456, "start_date": "2026-06-05", "completion_date": "2029-04-05", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 3, "location_summary": "Stockbridge, Georgia • Lenexa, Kansas • Seattle, Washington", "locations": [ { "city": "Stockbridge", "state": "Georgia" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07628049" }, { "nct_id": "NCT04919109", "title": "Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "CodaVax-RSV", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Codagenix, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "5 Years", "sex": "ALL", "summary": "6 Months to 5 Years" }, "enrollment_count": 41, "start_date": "2023-03-28", "completion_date": "2026-07-08", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 4, "location_summary": "Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more", "locations": [ { "city": "Lincoln", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "West Jordan", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919109" }, { "nct_id": "NCT04491877", "title": "Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infection" ], "interventions": [ { "name": "RSV vaccine formulation 1", "type": "BIOLOGICAL" }, { "name": "RSV vaccine formulation 2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Months", "sex": "ALL", "summary": "6 Months to 18 Months" }, "enrollment_count": 259, "start_date": "2020-09-17", "completion_date": "2023-04-13", "has_results": true, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 25, "location_summary": "Gardena, California • La Mesa, California • Los Angeles, California + 21 more", "locations": [ { "city": "Gardena", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Blackfoot", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT04491877" }, { "nct_id": "NCT06389487", "title": "A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSVPreF3 OA investigational vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1459, "start_date": "2024-04-29", "completion_date": "2025-03-18", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 16, "location_summary": "Glendale, Arizona • Phoenix, Arizona • North Hollywood, California + 13 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Hollywood", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06389487" }, { "nct_id": "NCT04126213", "title": "Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSV MAT 60 µg", "type": "BIOLOGICAL" }, { "name": "RSV MAT 120 µg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 534, "start_date": "2019-11-05", "completion_date": "2021-05-14", "has_results": true, "last_update_posted_date": "2021-12-13", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Nampa", "state": "Idaho" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04126213" }, { "nct_id": "NCT04138056", "title": "A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSVPreF3 formulation 3", "type": "BIOLOGICAL" }, { "name": "RSVPreF3 formulation 2", "type": "BIOLOGICAL" }, { "name": "Boostrix-ex-US", "type": "BIOLOGICAL" }, { "name": "Boostrix-US", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 509, "start_date": "2019-11-05", "completion_date": "2021-11-22", "has_results": true, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 4, "location_summary": "Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138056" }, { "nct_id": "NCT06564194", "title": "A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus (RSV)", "Infectious Disease" ], "interventions": [ { "name": "JCXH-108", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Immorna Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2024-09-25", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 3, "location_summary": "Jupiter, Florida • New Orleans, Louisiana • St Louis, Missouri", "locations": [ { "city": "Jupiter", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06564194" }, { "nct_id": "NCT03191383", "title": "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSV vaccine (GSK3003891A) formulation 1", "type": "BIOLOGICAL" }, { "name": "RSV vaccine (GSK3003891A) formulation 2", "type": "BIOLOGICAL" }, { "name": "RSV vaccine (GSK3003891A) formulation 3", "type": "BIOLOGICAL" }, { "name": "Placebo (Formulation buffer S9b)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 0, "start_date": "2017-07-11", "completion_date": "2017-07-14", "has_results": false, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-10-03T11:31:54.726Z", "location_count": 3, "location_summary": "Newton, Kansas • Syracuse, New York • Ellensburg, Washington", "locations": [ { "city": "Newton", "state": "Kansas" }, { "city": "Syracuse", "state": "New York" }, { "city": "Ellensburg", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03191383" } ] }